EGFR and non-small cell lung carcinoma: By helping the accurate prediction of the EGFR mutation status, CT radiomics-based methods can help clinicians identify NSCLC patients who may benefit from targeted therapies, improving treatment outcomes and reducing morbidity and mortality.